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Background: Patients with end-stage kidney disease (ESKD) have a high rate of mortality and specifically an
increased risk of sudden cardiac death (SCD). Impaired cardiac autonomic tone is associated with elevated risk of
SCD. Moreover, patients with ESKD are often vitamin D deficient, which we have shown may be linked to
autonomic dysfunction in humans. To date, it is not known whether vitamin D supplementation normalizes cardiac
autonomic function in the high-risk ESKD population. The VITamin D supplementation and cardiac Autonomic tone
in Hemodialysis (VITAH) randomized trial will determine whether intensive vitamin D supplementation therapies
improve cardiac autonomic tone to a greater extent than conventional vitamin D supplementation regimens in
ESKD patients requiring chronic hemodialysis.
Methods/Design: A total of 60 subjects with ESKD requiring thrice weekly chronic hemodialysis will be enrolled in
this 2x2 crossover, blinded, randomized controlled trial. Following a 4-week washout period from any prior vitamin
D therapy, subjects are randomized 1:1 to intensive versus standard vitamin D therapy for 6 weeks, followed by a
12-week washout period, and finally the remaining treatment arm for 6 weeks. Intensive vitamin D treatment
includes alfacalcidiol (activated vitamin D) 0.25mcg orally with each dialysis session combined with ergocalciferol
(nutritional vitamin D) 50 000 IU orally once per week and placebo the remaining two dialysis days for 6 weeks. The
standard vitamin D treatment includes alfacalcidiol 0.25mcg orally combined with placebo each dialysis session per
week for 6 weeks. Cardiac autonomic tone is measured via 24 h Holter monitor assessments on the first dialysis day
of the week every 6 weeks throughout the study period. The primary outcome is change in the low frequency: high
frequency heart rate variability (HRV) ratio during the first 12 h of the Holter recording at 6 weeks versus baseline.
Secondary outcomes include additional measures of HRV. The safety of intensive versus conventional vitamin D
supplementation is also assessed.
Discussion: VITAH will determine whether an intensive vitamin D supplementation regimen will improve cardiac
autonomic tone compared to conventional vitamin D supplementation and will assess the safety of these two
supplementation regimens in ESKD patients receiving chronic hemodialysis.
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More than 40,000 Canadians live with end-stage kidney
disease (ESKD)—roughly 1 out of every 1,000 people, a
number that has tripled over 20 years – and require life-
sustaining dialysis or transplantation [1]. Patients with
ESKD have a 20% annual mortality rate and an age-
specific cardiovascular death rate that is 10-100x higher
than the general population [2]. Sudden cardiac death
(SCD) accounts for more than a quarter of deaths in the
hemodialysis population, making it the leading cause of
death [2]. However, as is repeatedly reflected by negative
trials evaluating the effects of treatment of traditional
cardiovascular disease risk factors in patients with ESKD
[3-6], these deaths are not associated with typical coronary
artery disease, suggesting alternative mechanisms for SCD
in ESKD. As such, the pathophysiology of SCD in the
ESKD population is complex and believed to require the
interaction between a transient event (i.e. intermittent
hemodialysis) and underlying substrate. This process in-
duces electrical instability and ventricular arrhythmias
followed by hemodynamic collapse. Two factors specific
to ESKD patients that have emerged as potential con-
tributors to this SCD-susceptible state are altered min-
eral metabolism, including vitamin D deficiency, and
impaired cardiac autonomic tone [7-10].
Cardiac autonomic tone
Cardiac autonomic tone is derived from beat to beat
measurements of the time intervals between successive
QRS intervals, specifically RR intervals. Measurement of
HRV provides direct insight into abnormalities of the
autonomic nervous system, which consists of the sympa-
thetic nervous system (SNS) and the parasympathetic
(vagal) nervous system (PNS) limbs [7,11,12]. HRV as-
sesses the dynamic interaction and balance between the
SNS and PNS at the level of the heart, overall providing a
measure of cardiac autonomic competence [11,12]. The a
priori main outcomes of interest are measures of the fre-
quency domain as these parameters are direct measures of
cardiac autonomic tone [11] and are most commonly
described in the ESKD study population [10,13-15]. No
one parameter of HRV has been established as superior
in regards to their predictive ability as surrogate markers
for adverse cardiovascular events [7,16-19].
Decreased HRV is associated with an increased risk of
arrhythmias and cardiac death in both the general popu-
lation [7] and patients with ESKD on dialysis [8,9,12-15].
Further, alterations in HRV occur more frequently in
dialysis patients and corresponds with an increased risk
of SCD and cardiovascular mortality [9,13]. In a study of
30 ESKD patients, 53% had autonomic dysfunction, in
which 40% was isolated to the vagal (PNS) limb and 13%
had combined sympathetic and vagal dysfunction [20].
Similarly, HRV findings in a study of 239 hemodialysispatients demonstrated drastic sympathetic over-activity
and vagal withdrawal [15]. Another study of 383 patients
with ESKD on hemodialysis found that impaired cardiac
autonomic tone was independently associated with an
increased risk of all-cause and cardiovascular death after
adjustment for traditional cardiovascular risk factors [8].
Although HRV is a surrogate measurement, it has been
established as an important and validated, non-invasive
measure of cardiovascular-related mortality risk in the
ESKD population [12,13,20,21]. Consequently, interven-
tions enhancing measures of HRV, and therefore influen-
cing cardiac autonomic control, could potentially have
considerable survival benefits in the high-risk ESKD
patient population.
Vitamin D
There are multiple pharmacological analogues and for-
mulations of vitamin D available for clinical use [22,23].
To be effective in disorders resulting from vitamin D
deficiency, nutritional sources of vitamin D (cholecalcif-
erol, vitamin D3; and ergocalciferol, vitamin D2) must
undergo two enzymatic hydroxylations: 1) in the liver
to 25-hydroxyvitamin D (25OHD); 2) in the kidney,
1α-hydroxylase converts 25OHD to the biologically ac-
tive form of vitamin D, 1,25-dihydroxycholecalciferol
(calcitriol) or 1,25- dihydroxyergocalciferol [22,23]. The
liver hydroxylation is largely substrate driven, but the kid-
ney’s 1α-hydroxylase is very tightly regulated by hormones
(e.g. parathyroid hormone) and concentrations of calcium
and phosphate ions [22,23]. In the VITAH trial, we use
the following terminology for the specific vitamin D
analogues; nutritional vitamin D therapy is provided in
the form of ergocalciferol, and alfacalcidiol, is provided
as the active (activated) vitamin D derivative.
In ESKD, progressive loss of functional kidney activity
reduces the availability of 1α-hydroxylase within the
renal tissue, which in turn reduces 1,25-dihydroxyvita-
min D3 production [24]. ESKD patients are also com-
monly deficient in 25OHD due to decreased nutritional
intake from intensive dietary restrictions, lack of sun
exposure due to decreased mobility, and dysregulated
mineral metabolism [24].
In general, vitamin D deficiency is common and asso-
ciated with worse cardiovascular outcomes in both the
healthy [25] and ESKD [26] populations. Furthermore,
low vitamin D levels are associated with increased risk
of SCD in both non-ESKD [27] and ESKD patients
[28,29]. In relation to cardiovascular pathophysiology,
vitamin D has been shown to influence cardiac contract-
ility and myocardial calcium homeostasis in humans
[30-33]. Furthermore, a small study of hemodialysis pa-
tients showed that treatment with activated vitamin D
reduced the QT interval on electrocardiography [34].
Recently, we have not only shown that low vitamin D
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increases cardiovascular risk [35], but also that poor
vitamin D status is associated with an impaired ability to
maintain cardiac autonomic tone in response to endogen-
ous angiotensin II in healthy humans [36], a hormone that
is chronically upregulated in the ESKD population.
Furthermore, we have also demonstrated that vitamin
D supplementation is associated with normalization of
autonomic tone in response to an acute angiotensin II
stressor in healthy subjects [37]. As vagal activity is
markedly reduced in hemodialysis patients [15], it is
possible that vitamin D supplementation could im-
prove the cardiac autonomic response to stressors such
as hemodialysis. Regardless, the impact of vitamin D
therapy in the ESKD population, and on other surrogate
clinical measures of cardiovascular risk has not been
assessed. In an observational study, serum 25OHD pre-
dicted total and cardiovascular mortality in incident ESKD
patients, but this association was abolished in patients
provided therapy with calcitriol or its active analogues
[26]. This novel observation suggests that intensive
vitamin D therapy inclusive of 1,25-dihydroxyvitamin
D3 analogues as well as other vitamin D derivatives
may provide a more significant therapeutic and survival
benefit within the severely deficient ESKD population, and
thus provides the basis for assessing the therapeutic role
of intensive and conventional vitamin D supplementation
regimens in altering cardiac autonomic tone, as in the
VITAH trial.
Evidence to date supports the safety profile of vitamin D
therapy. Vitamin D deficiency is the norm in hemodialysis
patients and as such, vitamin D supplementation should
result in significant increase vitamin D levels. Secondly,
given there is significant controversy regarding the target
25-hydroxyvitamin D level in both the general and chronic
kidney disease population [38,39], we aimed to determine
the effect of delivered dose of vitamin D, rather than level
of vitamin D, on cardiac autonomic tone. Lastly, though
there is significant practice variation, the activated and nu-
tritional vitamin D doses chosen for the study reflect those
recommended in and typically prescribed to the end-stage
kidney disease population on hemodialysis [38].
Despite the high prevalence of vitamin D deficiency in
ESKD, current guidelines regarding correction of vitamin
D status are widely acknowledged to be opinion-based
and derived from biochemical endpoints [38]. The nutri-
tional vitamin D product (ergocalciferol) and dose pro-
posed within this protocol is identical to that suggested by
guidelines for treatment in the ESKD population [38,40].
Furthermore, treatment with other nutritional forms of
vitamin D3 at a dose of 15,000 IU/day × 1 month [41] and
40,000 IU/day over 28 weeks, followed by 10,000 IU/day ×
12 weeks [42] has been shown to be safe. A main clinical
concern with activated vitamin D supplementation in theESKD population is hypercalcemia, hyperphosphatemia
and reduction in parathyroid hormone levels. This
protocol employs the lowest possible dose of activated
vitamin D (alfacalcidiol) available to minimize signifi-
cant fluctuations in these biochemical values, though
the relative importance of these changes remains un-
quantified within the literature [43].
In summary, the evidence to guide treatment that may
minimize SCD and cardiovascular risk in ESKD is ex-
tremely limited. The VITamin D supplementation and
cardiac Autonomic tone in Hemodialysis (VITAH)
study is the first clinical trial to assess whether various
vitamin D therapies, specifically ingestion of the combin-
ation of activated and nutritional vitamin D compared to
activated vitamin D alone, influence cardiac autonomic




The primary aim of the VITAH trial is to determine
whether 6 weeks of intensive vitamin D supplementation,
consisting of alfacalcidiol 0.25mcg orally at every dialysis
session combined with ergocalciferol 50,000 IU orally once
per week and placebo the remaining 2 weekly dialysis ses-
sions, will influence HRV assessment of cardiac autonomic
tone, compared to 6 weeks of conventional therapy with
alfacalcidiol 0.25mcg and placebo orally at every dialysis
session. The secondary aim is to determine whether this
intensive vitamin D supplementation influences or modu-
lates independent activity of the sympathetic and vagal
limbs of the cardiac autonomic nervous system compared
to the conventional alfacalcidiol regimen.
We hypothesize that vitamin D supplementation will
increase all cardiac autonomic parameters, but that the
vitamin D treatment will specifically have the greatest
impact on vagal tone. We hypothesize that cardiosym-
pathovagal balance will decrease after vitamin D therapy
due to the fact that any increase in cardiosympathetic
tone will be offset by a larger increase in cardiovagal
tone.
Study design and setting
The VITAH Trial is a 2x2 cross-over, randomized-
controlled trial with blinding of subjects, investigators,
health care providers, as well as all study coordinators
and data analysts. Hemodialysis outpatients from the
Southern Alberta Renal Program will be randomized to
one of two treatment sequence arms; 6 weeks of intensive
vitamin D therapy (0.25 mcg alfacalcidiol at each dialysis
session plus 50,000 IU of ergocalciferol once per week and
placebo the remaining two weekly dialysis days), followed
by a 12 week washout, and 6 weeks of conventional vita-
min D therapy (0.25 mcg alfacalcidiol plus placebo at each
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ECG monitors are applied within the first hour of the first
weekly dialysis run at baseline and every 6 weeks through-
out the entire 24-week duration of the trial (Figure 1). The
study protocol will not impact on uremia clearance given
that the dialysis prescription will remain constant. Subject
recruitment began in January 2013 and will continue until
2016.
Ethical considerations
Ethical approval has been obtained from the Conjoint
Health Research Ethics Board (Project ID: E-24846) at
the University of Calgary as well as Health Canada (UC-
NEPH-2012001) for all study sites involved in the trial.
Two external bodies, a Data Safety Monitoring Board
and a Trial Steering Committee, will monitor study
progress.
Study interventions
The intervention is the vitamin D therapy sequence,
including 6 weeks of intensive therapy and 6 week of
conventional vitamin D therapy, or vice versa (Figure 1).
Given that the current clinical standard of care is use ofFigure 1 Overview of the VITAH trial.activated vitamin D (one of the top drug classes prescribed
as recently outlined in the United States Renal Data
System [44]) in the ESKD population, a placebo arm is
not included. Upon recruitment, participants who are
prescribed any form of vitamin D (either nutritional or
active) at that time will cease to take the medication
for 4 weeks, a valid washout period employed by the
PRIMO trial, a randomized controlled trial examining
the effects of activated vitamin D on cardiac structure
in subjects with non-dialysis dependent kidney disease
[45]. Participants who are not on any form of vitamin
D at the time of enrolment will be randomized to one
of the two treatment sequences immediately. All par-
ticipants will be randomized to Treatment Sequence 1
or Treatment Sequence 2, such that each participant
will ingest both vitamin D therapy regimens in a ran-
domized, blinded, placebo-controlled crossover design
and thus act as his/her own control. A 12 week wash-
out period was chosen between each 6 week vitamin D
treatment block to ensure that there are no carryover
effects from either study period as the t1/2 for alfacalcidiol
is approximately 4 hours, and the t1/2 for ergocalciferol is
19–48 hours [22,23,46].
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Eligible subjects are stable, thrice weekly hemodialysis
outpatients within the Southern Alberta Renal Program
in Calgary, Alberta. Inclusion and exclusion criteria are
outlined in Table 1. All patients in the Southern Alberta
Renal Program hemodialysis units will be reviewed. Indi-
viduals who meet inclusion criteria will be identified by
nephrologists or study investigators. After clearance
from the individual’s primary nephrologist, the name will
be forwarded to the study coordinators and recorded in
recruitment logs. Informed written consent will be ob-
tained from the participant, power of attorney or legal
substitute decision-maker. Once eligibility is confirmed
by reviewing the chart or from participant interview,
baseline clinical (i.e. ESKD etiology, comorbidities, car-
diovascular history, dialysis prescription and adequacy
details), demographic and medication data will be
obtained. Subjects will be randomized 1:1 to one of the
two treatment sequences.
Randomization and blinding
Subject identification codes and corresponding treat-
ment schedules, consisting of two treatment sequences
randomized in small random block sizes, were developed
by an independent biostatistician at the University of
Calgary prior to initiation of the trial. Following in-
formed consent, patients will be given the next available
subject identification code and are then randomized to
one of the two treatment sequences. The University of
Calgary Research Pharmacy is the sole entity that holds
the randomization list, and will prepare and dispense blis-
ter packs of the appropriate vitamin D supplementationTable 1 VITAH trial inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age ≥ 18 years • Any major cardiovascular event
within the last 6 months prior to
enrolment (this includes, but is
not limited to, new onset
arrhythmia, hospitalization for a
cardiovascular complication)
• Thrice weekly hemodialysis
outpatient within the Southern
Alberta Renal Program
• Physician consent to participate • Refusal to cease vitamin D therapy
for four (4) weeks prior to
initiation of the study
• Ability and agreement to cease
any prior vitamin D medication
for four (4) weeks prior to
initiation of the study
• Palliative status or metastatic
malignancy
• Ability to comprehend study
protocol and provide oral and
written consent in English
(native language or translated)
• Known or anticipated upcoming
change in dialysis modality
including transfer to peritoneal
dialysis, kidney transplant, or
change in current hemodialysis
schedule/durationfor distribution to each subject accordingly upon email
notification of recruitment. The study subjects, investiga-
tors, health care providers, study coordinators, and data
analysts will be blinded to both the randomization sched-
ule and subsequent treatment allocation.
On treatment days the hemodialysis nurses at each
study site will administer the study drug to the subjects
at the beginning of each dialysis session throughout the
24-week trial. Compliance with the vitamin D supple-
mentation will be recorded on study drug administration
schedules and checklists for each subject enrolled in the
trial. To ensure blinding, all vitamin D combinations will
be prepared in blister- packages by Research Pharmacy
marked only with the participant’s study identification
code. Each study capsule is packaged identically in1g soft
gel capsules to ensure blinding. Specifically, each study
capsule holds one 0.25mcg alfacalcidiol pill as well as a
placebo or 50,000 IU ergocalciferol pill. Ergocalciferol has
no distinct odour or taste. The Research Pharmacy has
manufactured the VITAH placebo pills within each cap-
sule to resemble the ergocalciferol pills in colour, shape,
odour, taste and consistency to allow for a blinded con-
trolled trial even if the study capsules are disassembled for
the subjects to facilitate ingestion. To ensure compliance
with the treatment, all blister-packs will be kept at the
respective hemodialysis unit and study medications will
be administered and recorded by the dialysis nurse (dir-
ectly-observed therapy). Ergocalciferol (vitamin D2), in
contrast to the other commercially available nutritional
vitamin D, cholecalciferol (vitamin D3), is only available
by prescription through a medical vendor and has been
labeled with a federal Drug Identification Number
through which product can effectively be tracked. This
method allows the investigators to determine whether
contamination is occurring during the study so it can be
reduced and to determine its extent during the analysis
phase. Subsequent statistical analyses will also be done
blinded to the above treatment allocation.
Data collection
Ambulatory electrocardiography (Holter) data is re-
corded for 18–24 hours using a standard bipolar 3-lead
configuration (GE Healthcare, SEER MC; Milwaukee,
USA). HRV is analyzed using a commercial Holter ana-
lysis system (MARS v. 7; GE Healthcare; Milwaukee,
USA). Power spectral density analysis, which transforms
the electrocardiographic signals into measures of fre-
quency domain HRV (representing activity of the cardiac
autonomic nervous system) are calculated. Autonomic ac-
tivity is categorized into spectral bands: total power (TP),
very-low frequency (VLF, 0.003-0.04 Hz), low-frequency
(LF, 0.04-0.15 Hz) and high-frequency (HF, 0.15-0.4 Hz)
domains [7,8,17-19]. Absolute LF and HF parameters
are then squared and log-transformed (ln ms [2]) and
Table 3 Baseline and ongoing data collection
Screening visit • Age, sex, target weight, duration on
dialysis, cause of end-stage kidney
disease, vascular access type
• Serum calcium, phosphate, parathyroid
hormone, Kt/V, 25-hydroxy vitamin D,
1,25-dihydroxy vitamin D
• Medication use
• GODIN leisure-time activity questionnaire
• DASI aerobic capacity questionnaire
Baseline study visit • Serum calcium, phosphate, parathyroid
hormone, Kt/V, 25OHD level, 1,25-
dihydroxy vitamin D level, catecholamines
• Renin, aldosterone, angiotensin II
• Delivered dose of dialysis (Kt/V)
• Power spectral analysis (LF, HF, LF:HF) and
time domain (SDNN, SDANN, pNN50%)
HRV parameters
Study visits every
6 weeks up to 24 weeks
• Serum calcium, serum phosphate,
parathyroid hormone, 25OHD,
1,25-dihydroxy-vitamin D, catecholamines
• Renin, aldosterone, angiotensin II
• Delivered dose of dialysis (Kt/V)
• Power spectral analysis (LF, HF, LF:HF) and
time domain (SDNN, SDANN, pNN50%)
HRV parameters
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pathovagal balance (LF:HF) is derived from these
measures. Time domain HRV measurements are also
calculated (Table 2) [7,8,17-19].
The specific physiological parameters which will be
assessed at each study visit throughout the study are de-
scribed in Table 3. A MEDRIO electronic database
(www.medrio.com) will be utilized for data entry after
collection at baseline and every 6 weeks up to 24 weeks.
Holter application and simultaneous blood draws will
be collected at each study visit in order to observe po-
tential vitamin D therapy-dependent changes in cardiac
autonomic tone, circulating renin-angiotensin system
activity markers, and mineral metabolism parameters
related to vitamin D metabolism including serum cal-
cium, phosphate, and parathyroid hormone. Blood sam-
ples collected from subjects at each study day are sent
to the on-site laboratory typically used for other routine
blood work at each of the study locations. Database ac-
cess and ability to update blinded data will be provided
only to the primary investigators.
Primary outcome
The primary outcome of the study is sympathovagal bal-
ance (LF:HF), interpreted as the overall balance on stimu-
latory and inhibitory cardiac autonomic control, from
baseline to the final study day within each 6 week treat-
ment block (0 and 6 weeks, 18 and 24 weeks). Comparison
of measured sympathovagal balance throughout each ofTable 2 Description of heart rate variability data to be





Low frequency (LF) Represents contribution of baroreflex
activity in overall cardiovascular control
High frequency (HF) Represents contribution of cardiac
parasympathetic/vagal nervous activity
Low to high frequency
ratio (LF:HF)
Represents the interplay between
sympathetic and parasympathetic limbs
of the autonomic nervous system
Standard deviation of the
normal
Wave (SDNN) Variation (in units of standard deviation)
between each successive R-wave in the
ECG recording
Standard deviation of the
average
Normal wave (SDANN) Average of the variation (in units of
standard deviation) between each
successive R-wave when comparing
multiple 5-minute sections of the ECG
recording
Percentage of normal wave
variation (pNN50%)
Percentage of normal R-waves that differ
from the wave directly before it by ≥50
millisecondsthe vitamin D supplementation treatment blocks as well
as the 12-week washout period will allow for statistical
interpretation of whether presence or absence of oral
vitamin D therapy alters cardiac autonomic function
within this population. An improvement in sympathovagal
balance can be interpreted by a downward shift in LF:HF,
in which a smaller value indicates greater contribution of
cardioprotective vagal activity (Table 2).
Secondary outcomes
The secondary outcomes include additional measures of
cardiac autonomic tone, including LF, HF, as well as time
domain parameters of HRV including the standard devi-
ation of the normal R-R interval (SDNN), standard devi-
ation of the average normal R-R interval (SDANN),
percentage of normal R waves occurring ≥ 50 ms after the
R waves immediately before (pNN50%), as well as blood
draw measurements related to vitamin D metabolism at
the beginning and termination of each 6 week treatment
block (Table 2).
Subject follow-up procedures
Subjects will be followed from trial entry until study
completion (24 weeks study period). The study coordin-
ator will review each subjects’ collected data at 6 week
intervals to record primary and secondary endpoints, as
well as to assess the safety and efficacy of the vitamin D
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medication may be discontinued for reasons associated
with concern for subject safety, or as requested by the
subject or primary nephrologist.
Study withdrawal
Given that the primary and secondary outcomes require
the measurement of cardiac autonomic tone with a Holter
monitor, follow up for these outcomes can only occur if
the subject is alive and accessible for monitoring. There-
fore, subjects will be censored and withdrawn from
follow-up under the following circumstances; subject or
primary nephrologist request, transfer to peritoneal dia-
lysis, kidney transplantation, transfer of subject to a
non-study hemodialysis unit, hospitalization, or death.
Upon withdrawal from the study, any data collected up
to that time will be utilized in a last observation carried
forward (LOCF) approach.
Statistical analysis
The primary analysis will test associations between inten-
sive and conventional vitamin D therapies and observed
fluctuations in LF:HF from baseline to 6 weeks later within
each treatment block utilizing a non-parametric paired
t-test. To further determine the relationships between
cardiac autonomic tone and specific vitamin D therapy
regimens, we will use a repeated measurements analysis
of variance model to account for the cross-over design
of the study utilizing Greenhouse-Geisser correction
values to account for multiple comparisons. Treatment,
treatment period, and treatment sequence will be analyzed
as fixed effects within the model, as well as additional
effect modifiers (gender, vitamin D, calcium, phos-
phate, parathyroid hormone). Additional analyses will
include a subgroup analysis for those subjects with dia-
betes mellitus as diabetes has been shown to alter pa-
rameters of cardiac autonomic tone and vitamin D
metabolism [9,21].
Sample size calculation
While we are not aware of any studies examining the use
of vitamin D on the primary outcome of this study, previ-
ous work by Kontopoulous et al. [47] has demonstrated
that post-myocardial infarction (MI) patients (n = 25)
randomized to receive 5–10 mg of quinapril (angiotensin
converting enzyme inhibitor) per day for 35 days immedi-
ately following an MI displayed a 46% reduction in LF:HF
from baseline to 6 weeks (mean ± SE: 10 ± 0.7; 5 ± 0.5),
while those randomized (n = 25) to receive 50–100 mg of
metoprolol per day for 35 days following an MI displayed
a similar 36% reduction in LF:HF from baseline to 6 weeks
(mean ± SE: 9 ± 0.6; 6 ± 0.4). As such, given that 1) vitamin
D deficiency is the norm in hemodialysis patients, 2)
vitamin D downregulates the renin-angiotensin system[24,25,35], and 3) increased RAS activity is associated
with alterations in cardiac autonomic tone [35-37], we
feel there is sufficient justification for the sample size
calculation herein. Based on these observations, we esti-
mate the standard deviation of the pooled difference in
LF:HF from both treatment sequences as 4.53. Using a
2 × 2 crossover design (2 sequences or treatment order-
ings and 2 time periods or occasions) and anticipating a
20% or larger reduction in LF:HF observed after 6 weeks
of treatment with combined vitamin D vs. the reduc-
tion observed after 6 weeks of treatment with alfacalci-
diol alone, we estimate that 54 subjects will be required
(α = 0.05, β = 0.9). In anticipation of a 10% dropout rate,
approximately 60 subjects in total will be recruited.Discussion
In summary, the VITAH trial will determine whether an
intensive vitamin D supplementation regimen will im-
prove cardiac autonomic tone compared to conventional
vitamin D supplementation in patients receiving chronic
hemodialysis. As the trial will remain relatively small in
nature, it is possible that potential sources of bias may
influence the results obtained. For example, subjects re-
cruited must be stable dialysis patients which may repre-
sent a different area of the patient spectrum in terms of
the benefit that may be derived from vitamin D supple-
mentation therapy. Furthermore, our study is limited to
the Calgary, Alberta area in Canada which may play a
role in the vitamin D levels of our subject population
based solely on geographical location and seasonal sun-
light exposure although current evidence would suggest
that a majority of dialysis patients are vitamin D defi-
cient regardless of geographical location [24,26-28]. The
evidence surrounding the relationship between various
vitamin D therapies and cardiovascular risk derived from
clinical trials is extremely scarce. The OPERA study by
Wang and colleagues [48] has recently demonstrated
that in subjects with non-dialysis dependent chronic kid-
ney disease, 52 weeks of daily paricalcitol supplementation
did not alter left ventricular mass, volume, or ejection
fraction. Critically, the study showed that cardiovascular-
related hospitalization rates were significantly reduced in
the vitamin D treatment group compared to placebo, sug-
gesting that vitamin D may affect cardiovascular risk and
underscoring the need for other cardiac parameters, such
as cardiac autonomic tone, to be evaluated in relation to
vitamin D supplementation. The VITAH trial will lend
much needed data to the literature pool, and moreover
conclusions drawn from this trial will provide quality evi-
dence towards the current equipoise which exists within
the discussion of the clinical efficacy of vitamin D in redu-
cing cardiovascular-specific risk in this growing vulnerable
chronic patient population.
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